Inpatient Outcomes Of Mechanical Circulatory Support Devices and Bridging to Transplantation in Hypertrophic Cardiomyopathy

Authors

Bilal Hussain, MD[a], Constantine Tarabanis, MD[b], Vishal Dhulipala, MD, FACC[c], Pradeepkumar Devarakonda, MD[c], Haisum Maqsood MD[d], Pedro Moreno, MD, FACC, FSCAI[c]

Affiliations

a) Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY

b) Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY

c) Cardiology Department, Icahn School of Medicine at Mount Sinai, New York, NY

d) Internal Medicine, Lincoln Medical Center, New York, NY

Word Count

Running Title

Mechanical Circulatory Support Devices in Hypertrophic Cardiomyopathy

Address For Correspondence

Bilal Hussain, MD

Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY

Address: 40 Cumberland St, Apt 2A, Brooklyn, NY, 11205

Email: bilalhussain1094@gmail.com

Phone: (857) 225-3392

Disclosures

Authors have nothing to disclose

Abstract

Objective

Understand the outcomes of mechanical circulatory support devices (MCSD) and heart transplantation (HT) in patients with underlying hypertrophic cardiomyopathy (HCM).

Introduction

HCM can rarely cause severe left ventricular outflow tract obstruction and apical ballooning presenting as cardiogenic shock necessitating the use of mechanical circulatory support devices (MCSD). Data on in-hospital outcomes of HCM patients placed on MCSD and receiving HT is limited.

Methods

The National Inpatient Sample (2016-2019) was used for the retrospective analysis of patients hospitalized for MCSD and HT using ICD-10 codes. These patients were divided into two cohorts, with and without HCM, and compared in terms of in-hospital mortality, trends in mortality rates, hospitalization costs and mean length of stay.

Results

Among 254170 patients hospitalized for MCSD and HT, 12,000 patients had underlying HCM. Underlying HCM was associated with increased odds of mortality in patients receiving left ventricular assist devices (LVAD) (OR 3.06, 95% CI 1.18-7.93, p=0.02) and short-term MCSD (OR 1.8, CI 1.29-2.5, p<0.001. HCM was not associated with increased mortality in patients hospitalized for HT (OR 1.05, CI 0.42-2.6, p=0.9). Patients with HCM undergoing MCSD and HT had a longer mean length of stay (26.6 vs 14.4 days, p<0.0001), and higher mean hospitalization charges ($977797 vs $497590, p<0.0001) as compared to non-HCM patients.

Conclusion

Underlying HCM is associated with increased in-hospital mortality in patients undergoing LVAD and short-term MCSD placement. Further prospective studies are required to expand our understanding of prognosis of HCM in patients undergoing MCSD and establish management guidelines.

Key Words

Hypertrophic Cardiomyopathy

Mechanical Circulatory Support Devices

Left Ventricular Assist Device (LVAD)

Heart Transplantation

Percutaneous Ventricular Assist Device (Impella)

Extracorporeal Membrane Oxygenation (ECMO)

Abbreviations

ECMO: Extracorporeal Membrane Oxygenation

HCM: Hypertrophic Cardiomyopathy

HT: Heart Transplantation

IABP: Intra-Aortic Balloon Pump

LV: Left Ventricle

LVAD: Left Ventricular Assist Device

LVOT: Left Ventricular Outflow Tract Obstruction

MCSD: Mechanical Circulatory Support Devices

Introduction

Hypertrophic cardiomyopathy (HCM) is a monogenic cardiac disorder caused by the autosomal dominant inheritance of variants in genes coding cardiac sarcomere proteins or sarcomere-related structures[1]. The pathophysiology of HCM can consist of diastolic dysfunction, dynamic left ventricular outflow tract obstruction (LVOTO), mitral regurgitation (MR) and arrhythmias[2]. Common ensuing complications of HCM include sudden cardiac death (SCD), heart failure (HF) and conduction blocks which are managed with implantation of cardiac devices[2]. Literature suggests that HCM can also rarely present with sudden development of severe and implacable LVOTO in association with severe mitral regurgitation, apical ballooning, decreased left ventricular (LV) ejection fraction, and refractory hypotension leading to cardiogenic shock[2]. Sherrid et al.[3] described this as 'Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy'.

It is crucial to diagnose if HCM is the cause of cardiogenic shock as it is challenging and the features might resemble acute coronary syndrome in an acute presentation. Coronary angiograms will be normal in these patients which might lead to the diagnosis of 'Takotsubo Cardiomyopathy' due to apical ballooning, however, these patients will have normal septal thickness, and no LVOTO unlike HCM. Management will be different in both of these patients. Some case studies have been reported for cardiogenic shock in HCM which has been treated with mechanical circulatory support devices (MCSD) including intra-aortic balloon pump (IABP), percutaneous ventricular assist device (Impella), extracorporeal membrane oxygenation (ECMO)[2,3]. If patient fails these therapies, urgent surgery is also indicated with surgical myomectomy. Relief of obstruction with these measures has shown to improve systolic

function and survival[3]. Furthermore, left ventricular assist devices (LVADs) have been described in HCM patients as a bridge to heart transplantation (HT)[4-6]. Data on the impact of MCSD and HT on HCM patient outcomes is limited to case studies[2,3]. To address this knowledge gap, we focus on data from hospitalizations during which MCSD and HT were performed to characterize the demographic, clinical characteristics and in-hospital outcomes of HCM patients as compared to their non-HCM counterparts.

Methods

Data source

Data was obtained from the National Inpatient Sample (NIS), a publicly available deidentified database of hospital inpatient stays in the United States, sponsored by the Agency for Healthcare Research and Quality as part of the Healthcare Cost and Utilization Project. Given the deidentified nature of the data, institutional review board approval was waived. The International Classification of Diseases-10th Edition-Clinical Modification (ICD-10-CM) codes were used to identify all patients aged 18 years or older hospitalized for MCSD and HT from January 1, 2016 to December 31, 2019. MCSD included LVAD and short-term MCSD (IABP, Impella, and ECMO. The study population's baseline characteristics were obtained using the corresponding ICD-10-CM codes (**Table S1**).

Study end points

Baseline characteristics and inpatient outcomes were compared between patients with and without HCM who had MCSD and HT performed. Prevalence trends in MCSD and HT in HCM were also investigated, while comorbidity burden was assessed using the Charlson Comorbidity Index (CCI)[7]. The study's primary outcome was in-hospital mortality compared between the two

cohorts. Secondary outcomes included mean length of stay (LOS) and hospitalization costs (adjusted for inflation).

Statistics

Categorical variables are presented as proportions and compared using Pearson chi-square (X^2) and Fisher's exact tests. Continuous variables are presented as mean with standard deviation and compared using Student' t-test. Univariate logistic regression models were used to investigate the unadjusted effect of underlying HCM on MCSD and HT in-hospital mortality. Multivariable logistic regressions accounted for gender, ethnicity, median household income, insurance, hospital bed-size, teaching status, location, CCI, coronary artery disease (CAD), congestive heart failure (CHF), arrhythmias, chronic pulmonary disease (CPD), liver disease, kidney disease, hypertension (HTN), hyperlipidemia (HLD), and diabetes mellitus (DM). Yearly trends for crude and adjusted mortality rates to account for covariates were tabulated using marginal standardization following logistic regression analyses. The secondary continuous outcomes of LOS and hospitalization costs were compared using multivariable linear regression models adjusting for the same aforementioned variables. All analyses were performed using HCUP recommended stratifying, clustering, and weighting samples with Stata Statistical Software (Version 17, Texas, StataCorp LLC).

Results

Baseline characteristics of MCSD and HT patients

Among 254170 patients hospitalized for MCSD, 1290 had underlying HCM. **Table 1** compares the baseline characteristics of patients who had MCSD and HT with and without HCM. Patients

who underwent MCSD and HT with underlying HCM had a lower mean age (55 vs. 63.6 years, p<0.001), a higher female proportion (46.5% vs. 29.7%, p<0.001) and a higher proportion with a history of CHF (69.4 vs 56.9%, *p*<0.001) as compared to those without HCM. Hospital characteristics were similar in the two cohorts with hospitalizations predominantly occurring in large urban teaching hospitals in the Southern US. Patients receiving a short-term MCSD had the higher mean age (60.9 years) than those receiving LVAD and HT (42.4, 42 years respectively) **(Table S2).**

Prevalence of MCSD and HT in HCM and Trends

Prevalence of MCSD and HT in patients with and without HCM is tabulated in **Figure 1** and **Table 2**. Patients with underlying HCM had consistently higher MCSD and HT rates than those without HCM (LVAD 0.05% vs 0.01%, p<0.001, short-term MCSD 0.4% vs 0.18%, p<0.001) (**Figure 1**). Majority of HCM had short-term MCSD (0.4%), followed by HT (0.2%), and LVAD (0.05%, **Figure 1**). Prevalence of HCM has been steadily trending up from 2016 to 2019 (0.14% to 0.17%, p<0.001) while MCSD and HT rates among HCM patients have remained stable (p>0.05) (**Figure 2, Table S3**).

Mortality Outcomes of MCSD and HT in HCM

Table 3 presents the univariate and multivariate logistic regressions for the effect of underlying HCM on mortality in patients undergoing MCSD and HT. Underlying HCM is associated with increased odds of mortality in patients undergoing LVAD implantation (OR 2.43, 95% CI 1.1-6.1, *p*=0.04), an effect preserved after multivariate adjustment (OR 3.06, 95% CI 1.18-7.93, *p*=0.02). Similarly, HCM is associated with increased odds of mortality in patients undergoing MCSD

implantation in both univariate (OR 2.25, 95% CI 1.66-3.04, *p*<0.001) and multivariate logistic regressions (OR 1.8, CI 1.29-2.5, p<0.001). Underlying HCM is not associated with increased mortality in patients hospitalized for HT (OR 1.05, CI 0.42-2.6, *p*=0.9).

Figure 3 delineates the temporal trends for adjusted mortality rates for MCSD and HT in patients with and without HCM (**Tables S4**, **S5**). Between 2016 and 2019, patients with HCM experienced a non-significant (p_{trend} = 0.09) increase in mortality from 2.5% to 3.5%, whereas their non-HCM counterparts had a significant (p_{trend} <0.001) increase in mortality from 1.9% to 2.1%. Patients with HCM hospitalized for MCSD and HT had significantly longer mean hospital lengths of stay as compared to non-HCM patients (26.6 vs 14.4 days, p<0.0001), and higher mean hospitalization charges ($977797 vs $497590, p<0.0001).

Discussion

The present study is the first to provide a comprehensive, comparative data analysis of the clinical characteristics and in-hospital outcomes of a HCM population admitted to US hospitals for MCSD and HT. This work builds upon prior HCM investigations of the NIS[8-10] to expand our understanding of contemporary HCM in-hospital outcomes for MCSD and HT.

We describe the baseline characteristics of patients with HCM receiving MCSD and HT (**Table 1**, **S2**) and trends in prevalence (**Figure 2**, **Table 2**). Notably, the congruent mean age of patients receiving LVADs and heart transplants is in line with the former serving as a bridge therapy to the latter[4-6]. On one hand, the percentage of HCM hospitalizations for MCSD and HT (**Figure 2**) remained stable over the examined time period. This is in agreement with largely unchanged management recommendations over the time period examined (2016-19)[11,12]. This

could also explain the unchanged adjusted, time-dependent in-hospital mortality rates (p = 0.09, **Figure 3**), since practice patterns should have accordingly remained relatively unchanged. On the other hand, the prevalence of HCM in the general population increases over the same time frame. This does not necessarily represent a true increase in the epidemiological disease burden, but instead could be explained by an increasing clinical recognition of this condition as many HCM patients can remain undiagnosed throughout life[13]. Regardless, the higher length of stay and hospitalization charges among HCM patients admitted for MCSD and HT compared to their non-HCM counterparts reflects the increased clinical complexity of the condition resulting in a greater healthcare utilization burden. Limited data exists on such healthcare utilization rates in HCM with one study expectedly noting higher HCM costs when a procedure is required, but lacking a comparison group[14].

Key among the present study's insights is the increased adjusted in-hospital mortality among HCM patients receiving LVAD or short-term MCSD as compared to their non-HCM counterparts (**Table 2**). The increased mortality risk, persisting even after adjusting for demographic, comorbidity and healthcare setting characteristics, raises the possibility that HCM pathophysiology renders patients a comparatively less optimal candidate for these advanced therapies in cardiogenic shock. As discussed earlier, besides case reports and series[2,3], data regarding the in-hospital outcomes related to IABP, Impella or ECMO use in the case of HCM is limited. Sherrid et al[3] suggested that LVOTO in HCM leads to high LV outflow peak gradient which in association with apical ballooning and wall motion abnormality can develop cardiogenic shock. This systolic dysfunction can be caused by supply-demand ischemia and afterload mismatch[3]. The patients in this case series required vasopressors, short-term MCSD

with IABP, Impella, and ECMO. While some of them failed these therapies and needed urgent surgical myomectomy. The patients survived acute shock phase and LV systolic function improved after LVOTO relief[3]. However, there are no known studies comparing the outcomes of MCSD in HCM compared to their non-HCM counter-parts. Hence, the increased risk of in-hospital mortality (adjusted OR 1.8 (1.29-2.50), *p* <0.001, **Table 2**) associated with MCSD use in HCM is a novel finding requiring further investigation to elucidate its underlying etiology.

A prior systematic review found a greater short-term mortality among a pooled cohort of 338 HCM and restrictive cardiomyopathy (RCM) LVAD recipients when compared to ischemic and dilated cardiomyopathy (ICM/DCM) patients[15]. In contrast, a retrospective study of 8 HCM/RCM LVAD recipients showed comparable early (30 days) and late (up to 1 year) mortality outcomes when compared again to their ICM/DCM counterparts[4]. This discrepancy in the literature could reflect differences in critical care practice patterns across US hospitals in patient selection and timing of LVAD placement and/or the difficulty in sufficiently powering a study to detect differences in an otherwise rare clinical occurrence. Regardless, our analysis of 110 LVAD recipients, supports the findings of the former study and additionally localizes the risk to a HCM-specific population, as RCM patients were excluded. The observed greater mortality can be explained by challenges in the applicability of LVADs to HCM pathophysiology, which entails thick LV walls with small associated cavities[15]. Indeed, prior investigations have correlated a smaller LV cavity size with increased mortality post-LVAD implantation in HCM and RCM patients[5,16]. Further investigations focused on HCM patients are needed to investigate whether the underlying cardiac pathophysiology or any ensuing noncardiac complications[15] can explain this mortality differential.

A key limitation of the present study is the use of an administrative database relying on billing codes rendering NIS entries susceptible to misclassification error, while the database's retrospective design precludes causal inferences. Additionally, the NIS lacks data pertaining to laboratory values, pharmacotherapy and imaging studies. Hence, we view this analysis as a tool for hypothesis generation to guide subsequent investigations.

Conclusion

The present study expands our understanding of in-hospital outcomes and practice patterns of HCM patients receiving MCSD and HT. Key among its insights, this study suggests that LVAD and short-term MCSD use are associated with an increased in-hospital mortality among HCM patients when compared to their non-HCM counterparts. This statistical association is important for clinicians to be aware of when making patient selection decisions for escalation to advanced therapies and should be further investigated in prospective studies.

Perspectives

What Is Known?

Hypertrophic cardiomyopathy can uncommonly cause left ventricular outflow tract obstruction and apical ballooning which can present as cardiogenic shock requiring mechanical circulatory support devices

What Is New?

This study highlights that underlying hypertrophic cardiomyopathy is associated with in-patient hospital mortality, hospitalization charges and length of stay in patients receiving left

ventricular assist devices and short term mechanical circulatory support devices including intra-aortic balloon pump, Impella, and extracorporeal membrane oxygenation.

What Is Next?

Prospective studies are required to further explore the outcomes of hypertrophic cardiomyopathy in mechanical circulatory support devices and establish management guidelines.

References

1.   Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy. J Am Coll Cardiol 2016;68:2871-2886.

2.   Caniato F, Andrei V, Bernardo P et al. Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning: Management With VA-ECMO and Myectomy. JACC Case Rep 2021;3:433-437.

3.   Sherrid MV, Swistel DG, Olivotto I et al. Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association 2021;10:e021141.

4.   Topilsky Y, Pereira NL, Shah DK et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail 2011;4:266-75.

5.   Patel SR, Saeed O, Naftel D et al. Outcomes of Restrictive and Hypertrophic Cardiomyopathies After LVAD: An INTERMACS Analysis. J Card Fail 2017;23:859-867.

6.   Muthiah K, Phan J, Robson D et al. Centrifugal continuous-flow left ventricular assist device in patients with hypertrophic cardiomyopathy: a case series. Asaio j 2013;59:183-7.

7.   Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.

8.   Rozen G, Elbaz-Greener G, Marai I et al. Utilization and Complications of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association 2020;9:e015721.

9.   Patlolla SH, Schaff HV, Nishimura RA, Geske JB, Dunlay SM, Ommen SR. Sex and Race Disparities in Hypertrophic Cardiomyopathy: Unequal Implantable Cardioverter-Defibrillator Use During Hospitalization. Mayo Clin Proc 2022;97:507-518.

10.   Gupta T, Harikrishnan P, Kolte D et al. Outcomes of acute myocardial infarction in patients with hypertrophic cardiomyopathy. Am J Med 2015;128:879-887.e1.

11.   Ommen SR, Mital S, Burke MA et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;142:e558-e631.

12.   Lakdawala NK, Olivotto I, Day SM et al. Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circulation: Genomic and Precision Medicine 2021;14:e003062.

13.   Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically

Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol

2016;117:1651-1654.

14.   Owens AT, Sutton MB, Gao W et al. Treatment Changes, Healthcare Resource

Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic

Cardiomyopathy: A Claims Database Study. Cardiol Ther 2022;11:249-267.

15.   Sreenivasan J, Kaul R, Khan MS et al. Left Ventricular Assist Device Implantation in

Hypertrophic and Restrictive Cardiomyopathy: A Systematic Review. Asaio j

2021;67:239-244.

16.   Grupper A, Park SJ, Pereira NL et al. Role of ventricular assist therapy for patients with

heart failure and restrictive physiology: Improving outcomes for a lethal disease. J Heart

Lung Transplant 2015;34:1042-9.

Figures

Figure 1: Prevalence of Mechanical Circulatory Support Devices and Heart Transplantation with and without Hypertrophic Cardiomyopathy: Patients with underlying hypertrophic cardiomyopathy (HCM) have higher left ventricular assist device (LVAD), short-term MCSD (IABP, Impella, ECMO) and heart transplantation (HT) rates than those without HCM.

Figure 2: Temporal trends in Mechanical Circulatory Support Devices and Heart Transplantation in Hypertrophic Cardiomyopathy: Left ventricular assist device (LVAD), short-term MCSD (IABP, Impella, ECMO) and heart transplantation (HT) rates among hypertrophic cardiomyopathy (HCM) patients have remained stable (p>0.05)

Figure 3: Temporal trends of adjusted mortality rates in Mechanical Circulatory Support Devices and Heart Transplantation with and without Hypertrophic Cardiomyopathy: From 2016 and 2019, hypertrophic cardiomyopathy (HCM) patients had a non-significant (p_{trend} = 0.09) increase in mortality, whereas their non-HCM counterparts had a significant (p_{trend} <0.001) increase in mortality.

Tables

Table 1: Baseline characteristics for MCSD and HT with and without HCM

| Patient Characteristic | MCSD and HT Patients (n=254170) | | | | p value |
| | With HCM (n=1290) | | Without HCM (n=252880) | | |
	Number of Patients (n)	Proportion (%)	Number of Patients (n)	Proportion (%)	
Age					
Mean Age (years, SD)	55 ±1.4		63.6 ±0.13		<0.001
Gender					
Male	690	53.5	193100	70.3	<0.001
Female	600	46.5	81615	29.7	
Ethnicity					
White	865	69.5	185700	70.8	0.03
African-American	215	17.2	30050	11.5	
Hispanic	80	6.4	25075	9.6	
Other Ethnicity	85	9.3	21650	8.1	
Co-Morbidities					
Coronary Artery Disease	665	51.6	234905	85.5	<0.001
Congestive Heart Failure	156305	69.4	895	56.9	<0.001
Arrhythmia	990	76.7	164030	59.7	<0.001
Hypertension	208755	76	920	71.3	0.07
Diabetes	325	40.8	112145	25.2	<0.001
Hyperlipidemia	495	38.4	151155	55	<0.001
Peripheral Artery Disease	90	7	15025	5.5	0.3
Chronic Pulmonary Disease	230	17.8	54635	19.9	0.4
Liver Disease	325	25.2	41375	15	<0.001
Kidney Disease	153035	72.9	940	55.7	<0.001
Anemia	840	65	137495	50	<0.001
Obesity	210	16.3	50930	18.5	0.3
Smoking	100	7.8	51260	18.7	<0.001
Charlson Comorbidity Index					
0	65	5	8930	3.3	0.001
1	295	22.9	41900	15.3	

2	290	22.5	62210	22.6	
≥3	640	49.6	161700	58.9	
Median Household Income					
$1-$49,999	270	21.5	77310	28.7	0.054
$50,000-$85,999	675	53.8	138035	51.3	
>$86,000	310	24.7	54185	20	
Insurance					
Medicare	495	38.5	147580	53.8	<0.001
Medicaid	185	14.4	31035	11.3	
Private Insurance	535	41.6	75775	27.6	
Others	70	5.5	19875	7.3	
Hospital Characteristics					
Hospital Bedsize					
Small	95	7.5	30155	11	0.001
Medium	220	17	68010	24.8	
Large	975	75.6	176575	64.2	
Location/Teaching Status					
Rural	<11	0.8	8930	3.2	<0.001
Urban Non-teaching	95	7.4	41775	15.2	
Urban Teaching	1185	91.2	224035	81.5	
Region					
Northeast	265	20.5	48695	17.6	0.3
Midwest	335	26	64735	23.6	
South	435	33.7	109750	40	
West	255	19.8	51560	18.8	
Ownership					
Government	195	15.1	26280	9.6	<0.001
Private	1095	84.9	248460	90.4	

HCM: Hypertrophic Cardiomyopathy, MCSD: Mechanical Circulatory Support Devices, HT: Heart

Transplantation

Table 2: Prevalence of MCSD and HT in patients with and without HCM

Modality	HCM Patients (n=222945)		Non-HCM Patients (n=142000000)		p value
	Number of Patients (n)	Proportion (%)	Number of Patients (n)	Proportion (%)	
LVAD	110	0.05	17015	0.012	<0.001
Short-Term MCSD	885	0.4	253285	0.18	<0.001
Heart Transplant	435	0.2	12740	0.009	<0.001

HCM: Hypertrophic Cardiomyopathy, LVAD: Left Ventricular Assist Device, MCSD: Mechanical

Circulatory Support Devices, HT: Heart Transplantation

Table 3: Effect of underlying HCM on in-hospital mortality in MCSD and HT

| Modality | Effect of Underlying HCM on Mortality in CDI | | | |
| | Univariate Logistic Regression | | Multivariate Logistic Regression | |
	Odd Ratio (95% CI)	p Value	Adjusted Odds Ratio (95% CI)	p Value
LVAD	2.43 (1.10-6.11)	0.04	3.06 (1.18-7.93)	0.02
Short-Term MCSD (IABP, Impella, ECMO)	2.25 (1.66-3.04)	<0.0001	1.8 (1.29-2.50)	<0.0001
Heart Transplant	1.05 (0.42-2.60)	0.09	-	-

ECMO: Extracorporeal Membrane Oxygenation, HCM: Hypertrophic Cardiomyopathy, HT: Heart Transplantation, IABP: Intra-Aortic Balloon Pump, LVAD: Left Ventricular Assist Device, MCSD: Mechanical Circulatory Support Devices,